RECENT COMMENTS

  • David Ryner (don't play with numbers): I agree with Duncan and thank you Kathy. I number myself amongst many who suffer from a cr [...]   »Read more
  • Duncan Jefferson (don't play with numbers): A very common sense article and one that should be taken on board by all in the Health "In [...]   »Read more
  • Ken Campbell (recording consultations): I am clinical information offider for a UK cancer charity. I often recommend to patients t [...]   »Read more
  • Frank (recording consultations): Yes I had a pt request a consultation with me - I am concerned about the medicolegal aspec [...]   »Read more
  • Nicola Nicolai, Lara Bellardita, Massimo Maffezzini, Tiziana Magnani, Riccardo Valdagni and the Prostate Cancer Program Multidisciplinary Team at Fondazione IRCCS Istituto Nazionale dei Tumori, Milan: The topic is of great interest, with good points in favour as well as against the referral [...]   »Read more
  • Marian marie: It was next to impossible to manage my Thyroid Cancer after I had a Thyroidectomy in 1976. [...]   »Read more
  • Paul CORNES (centralising cancer services): Thank you both - I enjoyed reading this. The best systematic review on the topic comes [...]   »Read more
  • Steven Vermeulen: I was diagnose with adenocarcinoma with unknown primary in Oct. 2009. I was 54 years old, [...]   »Read more
  • Wolfgang Grisold (cancer treatment: agesim): Thank you for raising this interesting issue. Personally , I have the impression that at l [...]   »Read more
  • Gloria Freilich (cancer treatment: ageism): In my experience, having worked in the field of breast cancer from l987 to 2008 in a Londo [...]   »Read more

Best Cancer Reporter Award

Issue 53
Tobacco tactics in the headlines
Issue 52
Me and my cancer
Issue 51
The origin of a special success
Issue 50
In the jungle of the miracle healers
Issue 47
Living with the timebomb of a childhood cancer
Issue 46
Is hope worth any price?  Award for German reporter who tackled a subject many prefer to avoid
Issue 45
Hope for me, and for others who come after:  award-winning article explores the impact of a new newtwork of early trial centres
Issue 44
The future of cancer as told through the story of Renee
Issue 41
Think before you ruin your patient's chance of parenthood
Issue 40
Desperately seeking a bone marrow match
Issue 39
Shining a light on nanoparticle therapy
Issue 38
Prize for journalists who tackled the taboo subject of rationing cancer therapies
Issue 34

Ten years reporting from the frontline: American journalist wins award for her coverage
Issue 33
The 'no miracle cure' story
Issue 32
Are we educating women to be afraid? UK health reporter questions the value of simplistic screening messages
Issue 28
Everyone deserves the best chance to survive
Issue 27
If nothing is done....Prize-winning article tells the story behind falling cancer mortality rates
Issue 26
The neglected magic bullet
Issue 24
"There's a shadow in your head"
Issue 23
Make prevention easy
Issue 22
My wife has breast cancer...
Issue 21
Do-it-yourself Chemotherapy Access
Issue 20
Polish reporter wins ESO award for coverage of colonscopy screening
Issue 16
From plan to practise
Issue 15
Reporting cancer from the inside
The subject is complex, the story is clear
Issue 14
Guardian journalist named Best Cancer Reporter
Issue 9
How the hostage-taking of Twist hit the mass media
Issue 8
Award for journalist who exposed failings in Hungary's cancer services


 
 

e-ESO.net

E-eso

Online educational resources Including e-grandrounds, weekly online meetings in collaboration with Nature Reviews Clinical Oncology - CME accredited!

Next live sessions:

The website is supported by an unrestricted educational grant provided by:

Founding sponsor

CancerWorld invites you to visit:

 
CancerWorld is a pioneering initiative of the European School of Oncology financially supported through Sharing Progress in Cancer Care, a collaborative programme between ESO and Amgen, Boehringer Ingelheim, Celgene, Eisai, Eli Lilly, Genomic Health, GlaxoSmithKline, Helsinn, Merck Serono, Novartis, Roche and Sanofi Aventis.